Journal of Gastric Cancer最新文献

{"title":"Long-term Survival Following Endoscopic Submucosal Dissection Versus Gastrectomy in Early Gastric Cancer Patients Aged 75 Years and Above: A National Retrospective Cohort Study in Korea.","authors":"Sangwon Lee, Yoon Jin Choi, Bang Wool Eom, Il Ju Choi, Choong-Kun Lee, Jungeun Park, Dong Ah Park, Kui Son Choi","doi":"10.5230/jgc.2025.25.e41","DOIUrl":"10.5230/jgc.2025.25.e41","url":null,"abstract":"<p><strong>Purpose: </strong>Despite a growing older adult population, few studies have compared the long-term outcomes of endoscopic submucosal dissection (ESD) with those of gastrectomy. This study examines long-term survival among older patients with early gastric cancer (EGC) treated with ESD versus gastrectomy.</p><p><strong>Materials and methods: </strong>This retrospective cohort study used data from the Korea Clinical Data Utilization Network for Research Excellence. Patients aged ≥75 with stage IA gastric cancer (diagnosed 2014-2015) who underwent ESD or gastrectomy were followed for 5 years. All-cause and cause-specific mortality were assessed using Cox proportional hazard models and propensity score matching.</p><p><strong>Results: </strong>Of the 442 patients (ESD, 269; gastrectomy, 173), the 5-year overall survival rates were 85.9% for ESD and 80.9% for gastrectomy (P=0.140). In patients aged ≥80, gastrectomy showed higher risks of total (adjusted hazard ratio [aHR], 3.29; 95% CI, 1.70-6.35) and gastric cancer-specific death (aHR, 7.18; 95% CI, 2.08-24.82) compared with ESD. In mucosa-confined lesions, gastrectomy also showed increased gastric cancer-specific mortality (aHR, 6.11; 95% CI, 1.93-19.35). The survival benefit of ESD was comparable to that of gastrectomy among patients aged 75-79 years and those with confined submucosal lesions.</p><p><strong>Conclusions: </strong>ESD may offer better outcomes than gastrectomy among older patients with stage IA gastric cancer, particularly those aged ≥80 or with mucosa-confined lesions. ESD and gastrectomy may provide similar survival outcomes among patients aged 75-79 years and those with submucosa-confined lesions. These findings support the use of adaptive treatment strategies in older patients with EGC.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 4","pages":"569-580"},"PeriodicalIF":3.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional Counseling for Patients With Gastric Cancer After Subtotal Gastrectomy: A Randomized Clinical Trial.","authors":"Ah Ron Lee, Jae-Moon Bae, Min-Gew Choi, Ji Yeong An, Eun-Mee Kim, Boram Park","doi":"10.5230/jgc.2025.25.e43","DOIUrl":"10.5230/jgc.2025.25.e43","url":null,"abstract":"<p><strong>Purpose: </strong>Evidence for the effectiveness of intensive nutritional counseling in reducing weight loss among patients who have undergone gastrectomy for gastric cancer is limited. We evaluated the effectiveness of intensive nutritional counseling in reducing weight loss after subtotal gastrectomy.</p><p><strong>Materials and methods: </strong>We conducted a prospective, parallel-assigned, double-blind randomized clinical trial to assess the effectiveness of intensive counseling (IC) compared with simplified counseling (SC) in reducing weight loss among patients who underwent subtotal gastrectomy for early gastric cancer. Patients were randomly assigned to either the IC or SC group between March 2021 and February 2023, with a final follow-up in September 2024. Patients in the IC group participated in an IC program delivered by specialized clinical dietitians. Patients in the SC group received only standard counselling sessions before discharge. The primary outcome was the percentage change in body weight from baseline to 12 months after subtotal gastrectomy.</p><p><strong>Results: </strong>A total of 258 patients were enrolled and randomized (122 in the IC group and 136 in the SC group), with 249 patients (96.5%) completing the 18-month follow-up period. At 12 months postgastrectomy, no statistically significant difference was observed in the percentage change in body weight between the 2 groups (0.09 percentage points; 95% confidence interval, -1.43 to 1.60). Other nutritional factors also showed no significant differences between the groups.</p><p><strong>Conclusions: </strong>Intensive nutritional counseling did not significantly reduce weight loss among gastric cancer patients after subtotal gastrectomy. Standard dietary counseling may be sufficient for dietary modification, although alternative approaches may be necessary.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT04798820.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 4","pages":"593-604"},"PeriodicalIF":3.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conditional Relative Survival Among Patients With Gastric Cancer Undergoing Surgery: A Hospital-Based Cohort Study.","authors":"Hyeree Park, Yo-Seok Cho, Do Joong Park, Hyuk-Joon Lee, Han-Kwang Yang, Yun-Suhk Suh, Seong-Ho Kong, Aesun Shin","doi":"10.5230/jgc.2025.25.e45","DOIUrl":"10.5230/jgc.2025.25.e45","url":null,"abstract":"<p><strong>Purpose: </strong>Conditional relative survival (CRS) estimates the probability of survival after surgery compared with the general population. We assessed 5-year CRS up to 5 years after gastric resection.</p><p><strong>Materials and methods: </strong>We analyzed 15,601 gastric cancer patients who underwent gastric resection between 1996 and 2018. Relative survival (RS) was defined as the ratio of observed survival in cancer patients to the expected survival in the general population. The 5-year CRS was the 5-year RS among patients who had survived a given number of years after surgery.</p><p><strong>Results: </strong>Five-year CRS increased from 87.2% at one year to 95.4% at 5 years post-surgery. The most substantial increase was observed in stage III cancer, from 53.2% at one year to 85.2% at 5 years. If patients survived 5 years after surgery, their 5-year CRS was 95.4% for those under 40, 96.4% for those aged between 40 and 64, 92.7% for those aged between 65 and 79, and 99.4% for those 80 or older. Recent surgeries showed higher 5-year CRS at the time of surgery and improved CRS during early follow-up. Although there could be concerns about death from postoperative complications, patients in their 80s did not show lower RS than younger patients. Across operation types, total gastrectomy yielded lower 5-year CRS than distal gastrectomy from baseline through 5 years after surgery.</p><p><strong>Conclusions: </strong>CRS improved over time, indicating that with careful candidate selection, surgery is safe, even for elderly patients. Additionally, patients who have undergone total gastrectomy may require nutritional support and long-term care.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 4","pages":"581-592"},"PeriodicalIF":3.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation and Overlap Between Claudin 18.2 and FGFR2b Overexpression: A Tissue Microarray Study With 1,538 Gastric Carcinomas.","authors":"Soomin Ahn, Inwoo Hwang, Kyoung-Mee Kim","doi":"10.5230/jgc.2025.25.e47","DOIUrl":"10.5230/jgc.2025.25.e47","url":null,"abstract":"<p><strong>Purpose: </strong>Claudin 18.2 (CLDN18.2) and fibroblast growth factor receptor 2b (FGFR2b) have recently emerged as promising therapeutic targets for advanced gastric cancer (GC). Before integrating CLDN18.2 and FGFR2b into routine practice, for optimal treatment planning, it is important to consider whether there exists an overlap between these biomarkers.</p><p><strong>Materials and methods: </strong>We evaluated CLDN18.2 expression in many patients with GC (n=1,538) using tissue microarrays that had been previously used to evaluate FGFR2b overexpression. We investigated the overlap between CLDN18.2 and FGFR2b expression and evaluated the clinicopathological features and prognostic implications of CLDN18.2 expression.</p><p><strong>Results: </strong>The CLDN18.2 positivity rates at 50% and 75% cutoffs were 34.7% and 24.4%, respectively. Heterogeneous expression was identified in 335 (23.5%) of 1426 cases with multiple tissue microarray cores. FGFR2b positivity at >0% cutoff was identified in 47 (3.1%) patients with more marked intratumoral heterogeneity than that observed with CLDN18.2. CLDN18.2 positivity (59.6%) in FGFR2b-positive GCs was significantly higher than that (33.9%) in FGFR2b-negative GCs (P<0.001). Concurrent FGFR2b- and CLDN18.2-positive GCs accounted for 1.8% of all patients, and FGFR2b-positive tumor cells were also positive for CLDN18.2 in approximately 75% of these cases. CLDN18.2 positivity was associated with poorly differentiated histology (P<0.001) and advanced pT and pN stages (P<0.03), but not with overall survival.</p><p><strong>Conclusions: </strong>CLDN18.2 and FGFR2b were significantly associated with each other, suggesting a considerable overlap. This finding may have important clinical implications on the optimal treatment strategy for CLDN18.2-positive GC.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 4","pages":"639-650"},"PeriodicalIF":3.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Comment on Rethinking Neoadjuvant Therapy: A Critical Evaluation of Exclusion Criteria in Gastric Cancer Surgery Studies.","authors":"Jawon Hwang, Woo Jin Hyung","doi":"10.5230/jgc.2025.25.e20","DOIUrl":"10.5230/jgc.2025.25.e20","url":null,"abstract":"","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 4","pages":"526-527"},"PeriodicalIF":3.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Proximal Gastrectomy Oncologically Justifiable for Advanced Siewert II/III Adenocarcinoma of the Esophagogastric Junction?","authors":"Haikuo Wang, Zhibin Ye, Yiming Lu, Haitao Hu, Yujuan Jiang, Wangyao Li, Xinxin Shao, Yantao Tian","doi":"10.5230/jgc.2025.25.e40","DOIUrl":"10.5230/jgc.2025.25.e40","url":null,"abstract":"<p><strong>Purpose: </strong>The oncological safety of proximal gastrectomy (PG) for advanced Siewert II/III adenocarcinoma of the esophagogastric junction (AEG) remains controversial. We compared the long-term oncological outcomes of PG and total gastrectomy (TG) to refine the indications for PG.</p><p><strong>Materials and methods: </strong>This dual-center retrospective study included 443 patients with pT2-4NanyM0 Siewert II/III AEG who underwent PG (n=192) or TG (n=251). Propensity score matching yielded 149 matched pairs. Perioperative outcomes, overall survival (OS), recurrence-free survival (RFS), and recurrence patterns were analyzed. Logistic regression analysis was used to assess risk factors for perigastric lymph nodes (PLN) recurrence after PG and key distal lymph nodes (KDLN) metastases after TG. The therapeutic index (TI) of KDLN metastases was calculated.</p><p><strong>Results: </strong>Although survival rates were lower after PG, no significant differences were observed in OS (hazard ratio [HR],1.39; P=0.109) or RFS (HR, 1.30; P=0.212). PG was associated with more local recurrences (24.12% vs. 8.7%; P<0.001), especially PLN metastases (13.4% vs. 5.4%; P=0.023). In subgroup analyses, PG was associated with worse OS in pT4 patients (HR, 2.17; P=0.006) and worse RFS in pN3 patients (HR, 2.37; P=0.011). In patients who underwent TG, tumor size >6 cm (OR, 3.72) and pT4 (OR, 13.9) predicted KDLN metastasis. Patients with KDLN metastases had significantly worse OS (HR, 2.51; P<0.001).</p><p><strong>Conclusions: </strong>TG is more suitable for patients with advanced Siewert II/III AEG with pT4, tumors >6 cm, or those with a high predicted risk of KDLN metastases. Accurate preoperative staging and intraoperative reassessment are essential for safe PG selection.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry Identifier: ChiCTR2500102562.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 4","pages":"541-555"},"PeriodicalIF":3.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Reduced-Port Robotic Gastrectomy Compared With the Conventional Laparoscopy in Korea (KLASS-13).","authors":"Sung Hyun Park, Sang-Hoon Ahn, Chang Min Lee, Han Hong Lee, Yun-Suhk Suh, Yoo Min Kim, Young Suk Park, Eun Hwa Kim, Hyoung-Il Kim","doi":"10.5230/jgc.2025.25.e42","DOIUrl":"10.5230/jgc.2025.25.e42","url":null,"abstract":"<p><strong>Purpose: </strong>Radical gastrectomy with lymphadenectomy remains the standard treatment for gastric cancer. Minimally invasive gastrectomy, particularly the reduced-port robotic gastrectomy (REPROG), has gained attention because of its precision and reduced invasiveness. This study aimed to establish a nationwide REPROG database in Korea and to evaluate its clinical outcomes.</p><p><strong>Materials and methods: </strong>All patients who underwent REPROG between February 2014 and December 2023 were analyzed. A comprehensive analysis of these patients, including perioperative outcomes, was conducted. To compare outcomes, a control group was selected from the 2019 Korea Nationwide Gastrectomy Database, focusing on patients receiving multiport conventional laparoscopic gastrectomy (CLG). A 1:2 propensity score matching was performed based on patient, tumor, and surgical characteristics. Perioperative outcomes, including the length of hospital stay, were compared between the matched cohorts.</p><p><strong>Results: </strong>A total of 1,071 patients who underwent REPROG were collected, of which 1,060 were included after exclusion and compared with CLG cases from a nationwide database. REPROG demonstrated a significant reduction in hospital stay, with a mean duration of 6.1 days compared with 7.8 days for the CLG (P<0.001). The incidence of major complications was similar between the 2 groups (1.9% vs. 2.4%, P=0.493). The conversion rate for REPROG was 0.19%. The annual number of patients receiving REPROG steadily increased, reaching 267 patients (24.9%) by 2023.</p><p><strong>Conclusions: </strong>Patients undergoing REPROG had a shorter hospital stay and a low conversion rate, indicating its potential as a treatment option for gastric cancer when performed by highly experienced surgeons.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 4","pages":"556-568"},"PeriodicalIF":3.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct Immunosuppressive Tumor Microenvironment in Gastric Cancer With Peritoneal Metastasis.","authors":"Hongsik Kim, Minsuk Kwon, Sun Kyung Lee, Seung-Myoung Son, Ok-Jun Lee, Soon Man Yoon, Hee Kyung Kim, Yaewon Yang, Ki Hyeong Lee, Hye Sook Han","doi":"10.5230/jgc.2025.25.e46","DOIUrl":"10.5230/jgc.2025.25.e46","url":null,"abstract":"<p><strong>Purpose: </strong>Immunotherapy combined with chemotherapy is the standard palliative treatment for gastric cancer. However, peritoneal metastases are often resistant to immunotherapy, underscoring the need to better understand the tumor immune microenvironment (TIME). In this study, we aimed to comprehensively analyze the TIME in peritoneal metastases of gastric cancer.</p><p><strong>Materials and methods: </strong>Paired single-cell suspensions from malignant ascites and peripheral blood mononuclear cells (PBMCs) were obtained from 27 patients with gastric cancer for multicolor fluorescence-activated cell sorting (FACS) analysis. Cell-free fluids from malignant ascites and plasma of 15 patients with gastric cancer, along with benign ascites from 15 patients with liver cirrhosis, were analyzed using multiplex enzyme-linked immunosorbent assay (ELISA). Paired samples of primary gastric tumors and metastatic peritoneal tumors from 12 patients were evaluated using multiplex immunohistochemistry (IHC).</p><p><strong>Results: </strong>FACS analysis revealed that T cells in malignant ascites expressed higher levels of immune checkpoint receptors (programmed death-1, T-cell immunoglobulin and mucin-domain containing-3, T-cell immunoglobulin and ITIM domain, lymphocyte activation gene-3, and cytotoxic T-lymphocyte antigen 4), and that CD8⁺ T cells exhibited terminal exhaustion (Eomes^highT-bet^low). Multiplex ELISA showed that soluble immunosuppressive factors (matrix metalloproteinase [MMP]-1, MMP-2, MMP-7, transforming growth factor-beta 1, hepatocyte growth factor, E-cadherin, vascular endothelial growth factor, and angiopoietin-2) were elevated in malignant ascites. Multiplex IHC showed lower CD4⁺ and CD8⁺ T cell densities in metastatic peritoneal tumors, which predominantly exhibited immunosuppressive TIME subtypes (immune-desert and intrinsic induction).</p><p><strong>Conclusions: </strong>Our results revealed distinct peritoneal immunosuppressive TIMEs in patients with gastric cancer with peritoneal metastasis.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 4","pages":"605-620"},"PeriodicalIF":3.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Reduced-Port Versus Conventional Laparoscopic Distal Gastrectomy for Early Gastric Cancer: A Multicenter, Randomized, Non-inferiority Trial (KLASS-12).","authors":"Hyoung-Il Kim, Hoseok Seo, Hoon Hur, Chang Min Lee, Sang-Hoon Ahn, Dong Jin Park, Yun-Suhk Suh, Oh Jeong, Sang-Yong Son, Mi Ran Jung, Young Suk Park, Dong-Wook Kim, Jeong Ho Song, Yoontaek Lee, Ji-Ho Park, Shin-Hoo Park, Sejin Lee, Seong-Ho Kong, Sun-Hwi Hwang, Jong Won Kim, Han Hong Lee","doi":"10.5230/jgc.2025.25.e34","DOIUrl":"10.5230/jgc.2025.25.e34","url":null,"abstract":"<p><strong>Purpose: </strong>This trial (KLASS-12) compares the efficacy and safety of reduced-port laparoscopic gastrectomy (RPLG) versus conventional 5-port laparoscopic gastrectomy (CPLG) for early gastric cancer (EGC).</p><p><strong>Materials and methods: </strong>This multicenter, open-label, randomized controlled trial enrolled patients diagnosed with gastric adenocarcinoma (T1N0M0) at 15 university hospitals in Korea. Participants underwent RPLG or CPLG with at least D1+ lymph node dissection. The primary aim of this study was to verify the non-inferiority of RPLG to CPLG in terms of postoperative 30-day complications.</p><p><strong>Results: </strong>From May 2022 to October 2023, 348 patients were randomly assigned to the RPLG and CPLG groups, with 174 patients in each group. After applying the exclusion criteria, 164 and 166 patients from the RPLG and CPLG groups, respectively, were analyzed. Complication rates were 10.4% and 9.2% for the RPLG and CPLG groups, in the intention-to-treat (ITT) population, and 10.4% vs. 7.2% in the per-protocol (PP) population. The risk difference was 0.012 (95% confidence interval [CI], -0.051 to 0.075) in the ITT population and 0.031 (95% CI, -0.030 to 0.093) in the PP population. These findings verified the non-inferiority of RPLG to CPLG, with a 10% margin. Additionally, the pain score on postoperative day 5 was significantly lower in the RPLG group (1.6% vs. 1.8%; P=0.028). The 2 groups showed no significant differences in the lymph node yield, conversion rate, or length of hospital stay. RPLG was not an independent risk factor for complications.</p><p><strong>Conclusions: </strong>RPLG is a feasible and safe alternative for patients with EGC, and its short-term outcomes are not inferior to those of CPLG.</p><p><strong>Trial registration: </strong>Clinical Research Information Service Identifier: KCT0006935.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 3","pages":"437-454"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Comments on \"The Impact of Different Types of Complications on Long-Term Survival After Total Gastrectomy for Gastric Cancer\".","authors":"Mi Ran Jung, Sung Eun Kim, Oh Jeong","doi":"10.5230/jgc.2025.25.e31","DOIUrl":"10.5230/jgc.2025.25.e31","url":null,"abstract":"","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"25 3","pages":"407-408"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144592952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}